topical Timolol maleate 0.5% eye drops — Competitive Intelligence Brief

topical Timolol maleate 0.5% eye drops (topical Timolol maleate 0.5% eye drops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic antagonist (non-selective). Area: Ophthalmology.

marketed Beta-adrenergic antagonist (non-selective) Beta-1 and beta-2 adrenergic receptors Ophthalmology Small molecule

Target snapshot

topical Timolol maleate 0.5% eye drops (topical Timolol maleate 0.5% eye drops) — Ain Shams University. Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
topical Timolol maleate 0.5% eye drops TARGET	topical Timolol maleate 0.5% eye drops	Ain Shams University	marketed	Beta-adrenergic antagonist (non-selective)	Beta-1 and beta-2 adrenergic receptors
oral Propranolol	oral Propranolol	Ahmed talaat ahmed aly	marketed	Non-selective beta-adrenergic antagonist (beta-blocker)	Beta-1 and beta-2 adrenergic receptors
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
amiodarone beta blocker sotalol	amiodarone beta blocker sotalol	Connolly, Stuart, M.D.	marketed	Beta-blocker with Class III antiarrhythmic activity	Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr)
betablocker titration	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	Keith G. LeBlanc, Jr, MD	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic antagonist (non-selective) class)

1. Ain Shams University · 1 drug in this class